Literature DB >> 30890566

Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions.

Gerard Clarke1, Kiran V Sandhu2, Brendan T Griffin2, Timothy G Dinan2, John F Cryan2, Niall P Hyland2.   

Abstract

The microbiome plays a key role in health and disease, and there has been considerable interest in therapeutic targeting of the microbiome as well as mining this rich resource in drug discovery efforts. However, a growing body of evidence suggests that the gut microbiota can itself influence the actions of a range of xenobiotics, in both beneficial and potentially harmful ways. Traditionally, clinical studies evaluating the pharmacokinetics of new drugs have mostly ignored the important direct and indirect effects of the gut microbiome on drug metabolism and efficacy. Despite some important observations from xenobiotic metabolism in general, there is only an incomplete understanding of the scope of influence of the microbiome specifically on drug metabolism and absorption, and how this might influence systemic concentrations of parent compounds and toxic metabolites. The significance of both microbial metabolism of xenobiotics and the impact of the gut microbiome on host hepatic enzyme systems is nonetheless gaining traction and presents a further challenge in drug discovery efforts, with implications for improving treatment outcomes or counteracting adverse drug reactions. Microbial factors must now be considered when determining drug pharmacokinetics and the impact that an evolving and dynamic microbiome could have in this regard. In this review, we aim to integrate the contribution of the gut microbiome in health and disease to xenobiotic metabolism focusing on therapeutic interventions, pharmacological drug action, and chemical biotransformations that collectively will have implications for the future practice of precision medicine.
Copyright © 2019 The Author(s).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30890566     DOI: 10.1124/pr.118.015768

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  47 in total

1.  Interactions between Environmental Exposures and the Microbiome: Implications for Fetal Programming.

Authors:  Sohini Banerjee; Melissa A Suter; Kjersti M Aagaard
Journal:  Curr Opin Endocr Metab Res       Date:  2020-10-03

Review 2.  Gutted! Unraveling the Role of the Microbiome in Major Depressive Disorder.

Authors:  Thomaz F S Bastiaanssen; Sofia Cussotto; Marcus J Claesson; Gerard Clarke; Timothy G Dinan; John F Cryan
Journal:  Harv Rev Psychiatry       Date:  2020 Jan/Feb       Impact factor: 3.732

3.  Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives.

Authors:  Ling Zou; Peter Spanogiannopoulos; Lindsey M Pieper; Huan-Chieh Chien; Wenlong Cai; Natalia Khuri; Joshua Pottel; Bianca Vora; Zhanglin Ni; Eleftheria Tsakalozou; Wenjun Zhang; Brian K Shoichet; Kathleen M Giacomini; Peter J Turnbaugh
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-22       Impact factor: 11.205

4.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

5.  Intestinal Microbiome and Metal Toxicity.

Authors:  Senait Assefa; Gerwald Köhler
Journal:  Curr Opin Toxicol       Date:  2019-09-30

Review 6.  The Gut Microbiome and Treatment-Resistance in Schizophrenia.

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2020-03

Review 7.  Probiotics and prebiotics in intestinal health and disease: from biology to the clinic.

Authors:  Mary Ellen Sanders; Daniel J Merenstein; Gregor Reid; Glenn R Gibson; Robert A Rastall
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07-11       Impact factor: 46.802

Review 8.  Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach.

Authors:  Emily J Cox; Dan-Dan Tian; John D Clarke; Allan E Rettie; Jashvant D Unadkat; Kenneth E Thummel; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Exosome-Like Nanoparticles From Lactobacillus rhamnosusGG Protect Against Alcohol-Associated Liver Disease Through Intestinal Aryl Hydrocarbon Receptor in Mice.

Authors:  Zelin Gu; Fengyuan Li; Yunhuan Liu; Mengwei Jiang; Lihua Zhang; Liqing He; Daniel W Wilkey; Michael Merchant; Xiang Zhang; Zhong-Bin Deng; Shao-Yu Chen; Shirish Barve; Craig J McClain; Wenke Feng
Journal:  Hepatol Commun       Date:  2021-02-05

10.  Oleacein Intestinal Permeation and Metabolism in Rats Using an In Situ Perfusion Technique.

Authors:  Anallely López-Yerena; Maria Pérez; Anna Vallverdú-Queralt; Eleftherios Miliarakis; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Pharmaceutics       Date:  2021-05-14       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.